vs
Side-by-side financial comparison of Guardian Pharmacy Services, Inc. (GRDN) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Guardian Pharmacy Services, Inc. is the larger business by last-quarter revenue ($336.6M vs $177.4M, roughly 1.9× Pacira BioSciences, Inc.). Guardian Pharmacy Services, Inc. runs the higher net margin — 4.0% vs 1.6%, a 2.4% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 2.2%).
CVS Pharmacy Inc. is an American retail corporation. A subsidiary of CVS Health, it is headquartered in Woonsocket, Rhode Island. Originally named the Consumer Value Stores, it was founded in Lowell, Massachusetts, in 1963.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
GRDN vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $336.6M | $177.4M |
| Net Profit | $13.5M | $2.9M |
| Gross Margin | 22.7% | — |
| Operating Margin | 5.3% | 3.9% |
| Net Margin | 4.0% | 1.6% |
| Revenue YoY | 2.2% | 5.0% |
| Net Profit YoY | 46.1% | — |
| EPS (diluted) | $0.21 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $336.6M | $177.4M | ||
| Q4 25 | $397.6M | $196.9M | ||
| Q3 25 | $377.4M | $179.5M | ||
| Q2 25 | $344.3M | $181.1M | ||
| Q1 25 | $329.3M | $168.9M | ||
| Q4 24 | — | $187.3M | ||
| Q3 24 | $314.4M | $168.6M | ||
| Q2 24 | — | $178.0M |
| Q1 26 | $13.5M | $2.9M | ||
| Q4 25 | $20.9M | — | ||
| Q3 25 | $9.8M | $5.4M | ||
| Q2 25 | $9.0M | $-4.8M | ||
| Q1 25 | $9.4M | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-122.0M | $-143.5M | ||
| Q2 24 | — | $18.9M |
| Q1 26 | 22.7% | — | ||
| Q4 25 | 21.5% | 79.5% | ||
| Q3 25 | 19.8% | 80.9% | ||
| Q2 25 | 19.8% | 77.4% | ||
| Q1 25 | 19.5% | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | 19.4% | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | 5.3% | 3.9% | ||
| Q4 25 | 7.7% | 1.2% | ||
| Q3 25 | 4.3% | 3.5% | ||
| Q2 25 | 3.7% | 4.7% | ||
| Q1 25 | 3.9% | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | -33.3% | -82.8% | ||
| Q2 24 | — | 15.9% |
| Q1 26 | 4.0% | 1.6% | ||
| Q4 25 | 5.3% | — | ||
| Q3 25 | 2.6% | 3.0% | ||
| Q2 25 | 2.6% | -2.7% | ||
| Q1 25 | 2.9% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -38.8% | -85.1% | ||
| Q2 24 | — | 10.6% |
| Q1 26 | $0.21 | $0.07 | ||
| Q4 25 | — | $0.05 | ||
| Q3 25 | — | $0.12 | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | — | $0.38 | ||
| Q3 24 | — | $-3.11 | ||
| Q2 24 | — | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $64.9M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $232.4M | $653.9M |
| Total Assets | $426.9M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $64.9M | $144.3M | ||
| Q4 25 | $65.6M | $238.4M | ||
| Q3 25 | $36.5M | $246.3M | ||
| Q2 25 | $18.8M | $445.9M | ||
| Q1 25 | $14.0M | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | $37.2M | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $0 | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | $34.3M | — | ||
| Q2 24 | — | — |
| Q1 26 | $232.4M | $653.9M | ||
| Q4 25 | $217.9M | $693.1M | ||
| Q3 25 | $195.5M | $727.2M | ||
| Q2 25 | $179.7M | $757.8M | ||
| Q1 25 | $163.2M | $798.5M | ||
| Q4 24 | — | $778.3M | ||
| Q3 24 | $133.9M | $749.6M | ||
| Q2 24 | — | $879.3M |
| Q1 26 | $426.9M | $1.2B | ||
| Q4 25 | $412.7M | $1.3B | ||
| Q3 25 | $390.0M | $1.3B | ||
| Q2 25 | $356.3M | $1.5B | ||
| Q1 25 | $334.0M | $1.6B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | $348.0M | $1.5B | ||
| Q2 24 | — | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.00× | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | 0.26× | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $6.1M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 0.45× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $6.1M | — | ||
| Q4 25 | $34.6M | $43.7M | ||
| Q3 25 | $28.2M | $60.8M | ||
| Q2 25 | $19.9M | $12.0M | ||
| Q1 25 | $17.6M | $35.5M | ||
| Q4 24 | — | $33.1M | ||
| Q3 24 | — | $53.9M | ||
| Q2 24 | — | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | $24.2M | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | 6.4% | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | 1.1% | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 0.9% |
| Q1 26 | 0.45× | — | ||
| Q4 25 | 1.65× | — | ||
| Q3 25 | 2.87× | 11.20× | ||
| Q2 25 | 2.21× | — | ||
| Q1 25 | 1.86× | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GRDN
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
